Evaluation of analgesic effect of perioperative Dexmedetomidine infusion in patients undergoing Major Neurosurgical procedures

A randomized single-blinded placebo control study of perioperative Dexmedetomidine infusion on 24 hour morphine consumption by patient controlled analgesia(PCA) in patients undergoing major neurosurgical procedures - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062663

Enrollment

Registered

2024-02-15

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D33- Benign neoplasm of brain and otherparts of central nervous system

Interventions

Intervention1: Dexmedetomidine: Intravenous infusion at rate of 0.5mcg per kg per hour during the entire course of surgical procedure Control Intervention1: Normal Saline: Calculated as for Dexmedetom

Eligibility

Inclusion criteria

Inclusion criteria: ASA PS 3 Elective Neurosurgical procedures

Exclusion criteria

Exclusion criteria: Cardiac disorders, Impaired renal, liver and pulmonary functions Intellectual disability Long term use of ACE inhibitors, Beta blockers, Sedatives, Psychiatric medications Emergency cases

Design outcomes

Primary

Measure	Time frame
24hr cumulative morphine consumptionTimepoint: 1hr, 2hr, 4hr, 6hr, 8hr, 12hr and 24 hr postoperative period	—

Secondary

Measure	Time frame
Incidence of nausea, VomitingTimepoint: 24 hours postoperative period;Post operative pain assessment using Numerical Rating ScaleTimepoint: 1, 2,4,6,8,12,24 hrs post operative period;Time of First analgesic requestTimepoint: 24 hours postoperative period	—

Countries

India

Contacts

Public ContactBharat Krishna

Saveetha Medical College

swathisekar@yahoo.com9566137571

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026